JUNS — JUPITER NEUROSCIENCES, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1679628 ·
Last close
$0.09
Market Cap
$4.34M
52W High
$0.53
52W Low
$0.08
ADV30
16,163,427
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 18,652 | 14,290 | -1,963,000 | -2,061,958 | 3,948,584 | 2,362,749 | 6,732,041 |
| Dec 2025 | 21,796 | — | -2,808,785 | -2,575,031 | 5,564,030 | 3,789,342 | 7,395,882 |
| Sep 2025 | 0 | — | -2,297,053 | -2,288,034 | 2,576,259 | 723,797 | 2,518,842 |
| Jun 2025 | 0 | — | -2,264,880 | -2,252,965 | 3,968,103 | 1,878,247 | 2,627,985 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,782,795
Investing CF
—
Financing CF
$5,439,075
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.25
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-36,728,984
Inventory
$148,068
Receivables
$0
ST Investments
—
EBIT TTM
$-8,994,553
Pretax Income TTM
$-9,177,988
Interest Exp TTM
$183,435
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$40,448
EBITDA
—
Free Cash Flow
$-2,619,687
Enterprise Value
$5,735,482
Total Cash
$2,362,749
Total Debt
$4,832,919
Shares Out
48,224,110
Trailing EPS
$-0.26
Book Value
$-0.08
ROE
-6529.2%
ROA
-130.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 21,796 | -8,908,721 | -8,644,897 | 5,564,030 | 7,395,882 | — | -5,413,736 |
| Dec 2024 | 0 | -3,091,282 | -2,439,625 | 6,202,409 | 2,030,401 | — | -3,911,004 |
| Dec 2023 | 0 | -3,870,771 | -4,783,689 | 148,592 | 5,949,946 | — | -480,953 |
| Dec 2022 | 233,281 | -3,432,447 | -4,957,580 | 235,944 | 7,380,028 | — | -1,248,504 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELAB | PMGC Holdings Inc. | $4.19M | $0.92 | — |
| TCRT | Alaunos Therapeutics, Inc. | $4.59M | $1.88 | — |
| SPRC | SciSparc Ltd. | $4.08M | $7.12 | — |
| CVSI | CV Sciences, Inc. | $4.08M | $0.02 | — |
| DRMA | Dermata Therapeutics, Inc. | $4.71M | $1.17 | — |
News headlines (Yahoo Finance, 1h cache)
Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva
2026-07-22 17:25 · Yahoo
Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS)
2026-07-21 14:27 · Yahoo
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
2026-07-21 11:13 · Yahoo
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
2026-07-21 11:00 · Yahoo
Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
2026-07-07 12:58 · Yahoo
Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream
2026-06-09 11:00 · Yahoo
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering
2026-05-26 16:00 · Yahoo
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
2026-05-20 18:38 · Yahoo
PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF)
2026-05-20 15:12 · Yahoo
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100
2026-05-20 12:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.